Look back at pharma news to August 26

28 August 2016
mergers-acquisitions-big

By Barbara Obstoj-Cardwell. Editor

Bernstein analyst Tim Anderson and team wonder if Pfizer winning the bidding war for Medivation with its $14 billion offer ( announced last Monday) is “something to be proud of,” reported Barron’s magazine.

At first pass, paying $80+/share for a stock that was trading in the $30′s just a few months ago feels pricey. What Pfizer gains is Medivation’s cut of Xtandi, and a Phase III PARP inhibitor, talazoparib, that Medivation itself recently bought from BioMarin. Medivation's prostate cancer treatment Xtandi generates close to $2 billion in annual sales and is projected to earn $4.8 billion in annual sales by 2020.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical